Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

Last updated: February 28, 2017
Sponsor: Ramathibodi Hospital
Overall Status: Completed

Phase

2/3

Condition

Kidney Failure

Kidney Disease

Hyponatremia

Treatment

N/A

Clinical Study ID

NCT03070353
ID 11-57-21
  • All Genders

Study Summary

A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Decompensated cirrhosis with acute kidney injury

  • Ager over 18 years old

Exclusion

Exclusion Criteria:

  • Having chronic kidney disease, severe heart or lung disease, severe sepsis

  • Pregnant

  • Receiving nephrotoxic agents

  • Having history of allergic to Dextran

Study Design

Total Participants: 10
Study Start date:
July 01, 2015
Estimated Completion Date:
June 30, 2016

Study Description

A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was < 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.